Biologics Market

1. Global Biologics Market Is Estimated To Witness High Growth Owing To Increasing R&D Activities And
Growing Demand For Biotech Products
The global biologics market is estimated to be valued at US$ 401.96 billion in 2023 and is expected to
exhibit a CAGR of 9.3% over the forecast period (2023-2030), as highlighted in a new report published by
Coherent Market Insights.
A) Market Overview:
The biologics market refers to the production and commercialization of products derived from living
organisms using biotechnology. These products include vaccines, antibodies, therapeutic proteins, and
gene therapies. Biologics offer a targeted approach to treat diseases and have gained significant
importance in the healthcare industry. They are extensively used in the treatment of various diseases,
including cancer, autoimmune disorders, and rare genetic diseases.
B) Market Dynamics:
The biologics market is driven by two key factors: increasing R&D activities and the growing demand for
biotech products.
1. Increasing R&D Activities: Pharmaceutical and biotech companies are investing heavily in research and
development activities to develop innovative biologics. This is driven by the need to address unmet
medical needs and improve patient outcomes. The advancements in biotechnology and genomics have
enabled the discovery of novel biologics with enhanced efficacy and reduced side effects.
For example, Novartis AG has been at the forefront of R&D in biologics, focusing on gene therapies and
personalized medicines. The company developed Kymriah, a CAR-T cell therapy for the treatment of
certain types of cancer. This therapy has shown promising results in clinical trials and has been approved
by regulatory authorities.
2. Growing Demand for Biotech Products: The increasing prevalence of chronic diseases and the growing
geriatric population have led to a surge in the demand for biotech products. Biologics offer targeted
treatment options for various diseases and have shown better clinical outcomes compared to traditional
therapies. The global biologics market has witnessed significant growth in recent years, driven by the high
demand for biotech products.

2. For instance, AstraZeneca PLC offers a range of biologic products for the treatment of respiratory,
cardiovascular, and metabolic diseases. Their biologic, Tagrisso, has been highly successful in the
treatment of non-small cell lung cancer.
C) Segment Analysis:
The biologics market can be segmented based on product type, application, and region. Based on product
type, the market can be categorized into vaccines, antibodies, therapeutic proteins, and gene therapies.
Among these, therapeutic proteins dominate the market due to their wide applications and effectiveness
in treating various diseases.
D) PEST Analysis:
- Political: The regulatory environment plays a crucial role in the biologics market. Stringent regulations
and approvals are required for the development and commercialization of biologic products. Changes in
political and regulatory policies can have a significant impact on the biologics market.
- Economic: The biologics market is driven by economic factors such as healthcare expenditure, insurance
coverage, and affordability of biotech products. Economic factors can influence the adoption and
accessibility of biologic therapies.
- Social: The increasing awareness about personalized medicine and targeted therapies has driven the
demand for biologics. Patients are willing to opt for biologic treatments due to their potential benefits
such as improved efficacy and reduced side effects.
- Technological: Technological advancements in biotechnology and genomics have revolutionized the
development and production of biologics. The use of genetic engineering, recombinant DNA technology,
and cell culture techniques has enabled the production of biotech products with higher efficacy and
specificity.
E) Key Takeaways:

3. - The global biologics market is expected to witness high growth, exhibiting a CAGR of 9.3% over the
forecast period, due to increasing R&D activities and the growing demand for biotech products.
- North America is the fastest-growing and dominating region in the biologics market, driven by the
presence of key players, favorable regulatory environment, and high healthcare expenditure.
- Key players operating in the global biologics market are Novartis AG, AstraZeneca PLC, Bayer AG, Sanofi
SA, Pfizer Inc, Merck & Co, Johnson and Johnson, GlaxoSmithKline PLC, Amgen Inc